CD34 and acute myeloid leukemia: Based on the characteristic, but heterogeneous genetic profiles of our patient cohort, we next performed global quantitative mass spectrometry (MS)-based proteomics to characterize the proteomic features of MDS/AML and compare them to CD34+ hematopoietic progenitor cells from healthy donors.